ConductScience.org, home

Paper16683074

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Hilgers W and 12 others. Invest New Drugs, 2006. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Papers, record 16683074. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16683074

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
PubMed
Journal
Invest New Drugs
PubMed
Year
2006
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.26
iCite
Revised in PubMed
2021-10-20
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hilgers WWerner
2Faivre SSandrine
3Chieze SStéphanie
4Alexandre JJérôme
5Lokiec FFrançois
6Goldwasser FFrançois
7Raymond EEric
8Kahatt CCarmen
9Taamma AAbdelkrim
10Weems GGarry
11MacDonald JRJohn R
12Misset JLJean-Louis
13Cvitkovic EEsteban

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CisplatinMajor topic
NeoplasmsMajor topic
SesquiterpenesMajor topic
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Staging

Source PubMed

Download CSV of topics

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114532976Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.Int J Oncol2003https://conductscience.org/library/papers/14532976PubMed
215685033Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial.Am J Clin Oncol2005https://conductscience.org/library/papers/15685033PubMed
310458260Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.J Clin Oncol1999https://conductscience.org/library/papers/10458260PubMed
410831281Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.Anticancer Drugs2000https://conductscience.org/library/papers/10831281PubMed
51591066Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study.Eur J Cancer1992https://conductscience.org/library/papers/1591066PubMed
6856436Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model.Cancer1977https://conductscience.org/library/papers/856436PubMed
710423161Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF).Biochem Pharmacol1999https://conductscience.org/library/papers/10423161PubMed
811118470Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.J Clin Oncol2000https://conductscience.org/library/papers/11118470PubMed
910521061Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer.Am J Clin Oncol1999https://conductscience.org/library/papers/10521061PubMed
101244564Prediction of creatinine clearance from serum creatinine.Nephron1976https://conductscience.org/library/papers/1244564PubMed
1110736422Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).Biochem Pharmacol2000https://conductscience.org/library/papers/10736422PubMed
1210655437
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
J Natl Cancer Inst2000https://conductscience.org/library/papers/10655437PubMed
139000568Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.Cancer Res1997https://conductscience.org/library/papers/9000568PubMed
149797706Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft.Eur J Cancer1998https://conductscience.org/library/papers/9797706PubMed
152402017Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity.J Natl Cancer Inst1990https://conductscience.org/library/papers/2402017PubMed
1612566077Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.Biochem Pharmacol2003https://conductscience.org/library/papers/12566077PubMed
17498155Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.Cancer Treat Rep1979https://conductscience.org/library/papers/498155PubMed
189416969Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).Biochem Pharmacol1997https://conductscience.org/library/papers/9416969PubMed
1915161692Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.Clin Cancer Res2004https://conductscience.org/library/papers/15161692PubMed
2015642808Cone damage in patients receiving high-dose irofulven treatment.Arch Ophthalmol2005https://conductscience.org/library/papers/15642808PubMed

See all 26 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
37996508Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.Sci Rep2023https://conductscience.org/library/papers/37996508PubMed
19938810Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven.J Org Chem2009https://conductscience.org/library/papers/19938810PubMed
18227973Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.Invest New Drugs2008https://conductscience.org/library/papers/18227973PubMed
17628744A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.Invest New Drugs2007https://conductscience.org/library/papers/17628744PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
NPEPPS9520PubTator's text mininghttps://conductscience.org/library/genes/9520

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16683074

GET https://conductscience.org/api/papers/v1/16683074/references?page=2